<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sbarouni, E</style></author><author><style face="normal" font="default" size="100%">Kroupis, C.</style></author><author><style face="normal" font="default" size="100%">Kyriakides, ZS</style></author><author><style face="normal" font="default" size="100%">Koniavitou,K.</style></author><author><style face="normal" font="default" size="100%">Kremastinos, D.T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Cell adhesion molecules in relation to simvastatin and hormone replacement therapy in coronary artery disease</style></title><secondary-title><style face="normal" font="default" size="100%">Eur.Heart J.</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Anticholesteremic Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Blood</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell adhesion molecules</style></keyword><keyword><style  face="normal" font="default" size="100%">Cholesterol,LDL</style></keyword><keyword><style  face="normal" font="default" size="100%">Complications</style></keyword><keyword><style  face="normal" font="default" size="100%">Coronary Disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Cross-Over Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Therapy,Combination</style></keyword><keyword><style  face="normal" font="default" size="100%">Estrogens,Conjugated (USP)</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Greece</style></keyword><keyword><style  face="normal" font="default" size="100%">Hormone Replacement Therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Hypercholesterolemia</style></keyword><keyword><style  face="normal" font="default" size="100%">Intercellular Adhesion Molecule-1</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Medroxyprogesterone Acetate</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Simvastatin</style></keyword><keyword><style  face="normal" font="default" size="100%">therapeutic use</style></keyword><keyword><style  face="normal" font="default" size="100%">therapy</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2000</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2000/06//</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">PM:10901509</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">21</style></volume><pages><style face="normal" font="default" size="100%">975 - 980</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">AIMS: To assess the effect of simvastatin, hormone replacement therapy and their combination on soluble cell adhesion molecules and plasma lipids, in hypercholesterolaemic post-menopausal women with coronary artery disease. METHODS: We studied 16 post-menopausal women with coronary artery disease and hypercholesterolaemia (total cholesterol &gt;200mg x dl(-1) and LDL cholesterol &gt;130 mg x dl(-1)). We compared simvastatin (20 mg daily) with hormone replacement therapy (0.625 mg conjugated oestrogen and 2.5 mg medroxyprogesterone acetate daily) and their combination, in a randomized, crossover, placebo controlled study. Each treatment period was 8 weeks long with a 4 week washout interval between treatments. Circulating cell adhesion molecules and plasma lipids were evaluated at the end of each treatment period. RESULTS: All three active treatments--simvastatin, hormone replacement therapy and the combination therapy--significantly reduced total and LDL cholesterol, compared to placebo (P&lt;0.001). Only hormone replacement therapy, alone and in combination with simvastatin, significantly decreased lipoprotein(a) when compared to placebo (P&lt;0.05), whereas simvastatin had no significant effect. Likewise, hormone replacement therapy and the combination therapy significantly reduced the intercellular adhesion molecule (ICAM-1) plasma levels (P=0.03 and P=0.02, respectively), while simvastatin, which was superior to hormone replacement therapy in lowering total and LDL cholesterol, did not modify ICAM-1 levels; the combination therapy was not more effective than hormone replacement therapy alone in ICAM-1 reduction. Neither the effect, on any treatment when compared to placebo, of VCAM-1 nor E-selectin levels differed significantly. CONCLUSIONS: Hormone replacement therapy may limit the inflammatory response to injury by modulating the expression of cell adhesion molecules from the endothelial cells, possibly in association with lipoprotein (a) reduction</style></abstract><issue><style face="normal" font="default" size="100%">12</style></issue><notes><style face="normal" font="default" size="100%">DA - 20001018IS - 0195-668X (Print)IS - 0195-668X (Linking)LA - engPT - Clinical TrialPT - Journal ArticlePT - Randomized Controlled TrialRN - 0 (Anticholesteremic Agents)RN - 0 (Cell Adhesion Molecules)RN - 0 (Cholesterol, LDL)RN - 0 (Estrogens, Conjugated (USP))RN - 126547-89-5 (Intercellular Adhesion Molecule-1)RN - AGG2FN16EV (Simvastatin)RN - C2QI4IOI2G (Medroxyprogesterone Acetate)SB - IM</style></notes></record></records></xml>